1 in 10 adults estimated to have dolor crónico disorders... esperado to increase further in super-aged society
Aiming to provide new options in the tratamiento del dolor mercado with 'dirigido a canales iónicos therapeutics'
[BioTimes] The number of dolor crónico pacientes is increasing worldwide. The International Association for the Study of Pain (IASP) estimates that 20% of adults worldwide, and the Korean Pain Society estimates that 1 in 10 Korean adults suffer from dolor crónico. Some predict that as society transitions from an aging to a super-aged society, the number of dolor crónico pacientes will increase further.
The problem is that while tratamiento del dolor using narcotic or analgésico no narcóticos shows generally good eficacia, the indications are not specialized, resulting in low clinical effectiveness. En particular, with increasing cases of dizziness, drowsiness, analgésico narcótico addiction, and misuse/abuse, new approaches to tratamiento del dolor are being demanded.
RudaCure focused on the fundamental causes of pain while minimizing efectos secundarios. La empresa aims to provide a new paradigm for the tratamiento del dolor mercado with 'dirigido a canales iónicos therapeutics.'
We met with RudaCure CEO Yongho Kim, who está desarrollando a drug targeting the TRPV1 (Transient Receptor Potential Vanilloid 1) canal iónico that directly modulates pain-related canal iónicos in sensory neurons.
Q: Please introduce la empresa briefly.
A: RudaCure was founded in 2018 and está desarrollando new drugs targeting the TRPV1 canal iónico, which plays a core role in pain signal transmission. TRPV1 is the most validated target in the pain field, and while many large empresas farmacéuticas have attempted desarrollo, achieving eficacia while managing efectos secundarios ha sido a chronic challenge. We are developing next-generation tratamientos that overcome this through our proprietary approach.
Q: What are the main pipelines?
A: Our main pipelines are 'RCI001,' a tratamiento de la enfermedad de ojo seco, and 'RCI002,' a analgésico no narcótico. RCI001 indirectly modulates TRPV1 downstream signals to suppress inflammation, rapidly restoring both signs and symptoms of ojo seco within 4 weeks. We recently obtuvo FDA Phase 2 IND aprobación, allowing us to begin ensayo clínicos in the US. RCI002 simultaneously targets both TRPV1 and MOR to achieve dual efectos analgésicos, showing eficacia at very low doses without the addiction risk of analgésicos narcóticos.
Q: What differentiates you from competitors?
A: Unlike conventional TRPV1 antagonists that directly block the channel and cause efectos secundarios like body temperature elevation, our drugs indirectly modulate the TRPV1 downstream pathway to maintain seguridad while maximizing eficacia. This is the biggest differentiator. Also, our AI-based desarrollo de fármacos plataforma 'RuCIA' enables efficient desarrollo cycles.
Q: What are your future plans?
A: We plan to proceed with Phase 2 ensayo clínicos for RCI001 in the US and Korea, and advance RCI002 to Phase 1 ensayo clínicos. También estamos pursuing global transferencia de tecnologías and are in discussions with multiple overseas empresas farmacéuticas. Our mid-to-long-term goal is an IPO by 2027.